Accumulated costs and impacts until | |||||
2018 | 2020 | 2030 | 2040 | 2050 | |
Total infections averted | |||||
Status quo | 203 | 689 | 5148 | 10 019 | 13 690 |
Screening from 60 | 434 | 1259 | 6475 | 11 516 | 15 231 |
Screening from 40 | 707 | 1936 | 8197 | 13 561 | 17 374 |
Screening from 20 | 784 | 2129 | 8685 | 14 146 | 17 992 |
Total hepatitis C-related deaths averted | |||||
Status quo | 21 | 84 | 1194 | 3168 | 4913 |
Screening from 60 | 33 | 128 | 1456 | 3536 | 5310 |
Screening from 40 | 38 | 144 | 1616 | 3888 | 5798 |
Screening from 20 | 38 | 144 | 1623 | 3908 | 5835 |
Total costs (US$ millions) | |||||
Status quo | 202 | 373 | 954 | 1252 | 1386 |
Screening from 60 | 451 | 603 | 1141 | 1427 | 1558 |
Screening from 40 | 795 | 926 | 1409 | 1670 | 1789 |
Screening from 20 | 965 | 1091 | 1558 | 1815 | 1931 |
Average cost per infection averted (US$) | |||||
Status quo | 998 170 | 540 669 | 185 297 | 124 948 | 101 208 |
Screening from 60 | 1 039 029 | 478 851 | 176 287 | 123 948 | 102 276 |
Screening from 40 | 1 124 565 | 478 359 | 171 848 | 123 177 | 102 971 |
Screening from 20 | 1 230 596 | 512 246 | 179 437 | 128 302 | 107 320 |
Average cost per deaths averted (US$) | |||||
Status quo | 9 867 435 | 4 456 291 | 799 119 | 395 182 | 282 029 |
Screening from 60 | 13 498 659 | 4 720 165 | 783 710 | 403 650 | 293 380 |
Screening from 40 | 21 007 361 | 6 420 448 | 871 637 | 429 658 | 308 537 |
Screening from 20 | 25 439 608 | 7 536 489 | 960 442 | 464 426 | 330 929 |
Incremental cost-effectiveness ratio (ICER) | |||||
Incremental infection averted | |||||
Status quo | 203 | 689 | 5148 | 10 019 | 13 690 |
Screening from 60 | 231 | 570 | 1326 | 1497 | 1541 |
Screening from 40 | 273 | 677 | 1723 | 2046 | 2143 |
Screening from 20 | 78 | 193 | 488 | 585 | 618 |
Incremental deaths averted | |||||
Status quo | 21 | 84 | 1194 | 3168 | 4913 |
Screening from 60 | 13 | 44 | 263 | 368 | 397 |
Screening from 40 | 4 | 16 | 160 | 352 | 489 |
Screening from 20 | 0 | 0 | 6 | 20 | 36 |
Incremental costs (US$ millions) | |||||
Status quo | 202 | 373 | 954 | 1252 | 1386 |
Screening from 60 | 248 | 230 | 187 | 176 | 172 |
Screening from 40 | 344 | 323 | 267 | 243 | 231 |
Screening from 20 | 170 | 164 | 150 | 144 | 142 |
Incremental cost-effectiveness ratio (infection averted) | |||||
Status quo | 998 170 | 540 669 | 185 297 | 124 948 | 101 208 |
Screening from 60 | 1 074 867 | 404 093 | 141 311 | 117 260 | 111 770 |
Screening from 40 | 1 260 665 | 477 442 | 155 163 | 118 834 | 107 909 |
Screening from 20 | 2 197 194 | 852 683 | 306 943 | 247 192 | 229 604 |
Incremental cost-effectiveness ratio (deaths averted) | |||||
Status quo | 9 867 435 | 4 456 291 | 799 119 | 395 182 | 282 029 |
Screening from 60 | 19 277 053 | 5 220 339 | 713 661 | 476 444 | 433 832 |
Screening from 40 | 77 654 439 | 19 588 848 | 1 673 009 | 691 156 | 473 235 |
Screening from 20 | Dominated | Dominated | 23 046 095 | 7 199 017 | 3 903 209 |
Table shows difference between scenarios in the accumulated costs and health impacts from 2017 until year indicated. We used the 2016 year-average exchange rate29 to convert Korean won to US dollars (KRW 1160) and a discount rate of 3%.30